Lexicon Pharmaceuticals Inc
LXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06B
Close$
$-0.39
117% downside
Current Fair Value
117% downsideOvervalued by 117% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.06 Billion |
|---|---|
| Enterprise Value | $1.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 1.05 |
| Outstanding Shares | 400,240,000 |
Return
| Return on Equity | -12.86% |
|---|---|
| Return on Assets | -9.71% |
| Return on Invested Capital | -8.65% |
Valuation & Multiples
| P/E Ratio | -33.47 |
|---|---|
| PEG | 34.91 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.7 |
| Enterprise Value to EBIT | -45.71 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$9.79 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$5.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 8.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 89.07% |
|---|---|
| Total Invested | $34,423▼ 99.99% |
| Investors Holding | 6▼ 135.00% |
ESG Score
No data